- Home
- DERM vs VTYX Comparison
DERM vs VTYX Comparison
Compare DERM & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- VTYX
- Stock Information
- Founded
- DERM 2014
- VTYX 2018
- Country
- DERM United States
- VTYX United States
- Employees
- DERM N/A
- VTYX N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- DERM Health Care
- VTYX Health Care
- Exchange
- DERM Nasdaq
- VTYX Nasdaq
- Market Cap
- DERM 140.0M
- VTYX 154.9M
- IPO Year
- DERM 2021
- VTYX 2021
- Fundamental
- Price
- DERM $6.25
- VTYX $1.07
- Analyst Decision
- DERM Strong Buy
- VTYX Buy
- Analyst Count
- DERM 2
- VTYX 4
- Target Price
- DERM $10.00
- VTYX $11.33
- AVG Volume (30 Days)
- DERM 103.6K
- VTYX 1.4M
- Earning Date
- DERM 05-12-2025
- VTYX 05-08-2025
- Dividend Yield
- DERM N/A
- VTYX N/A
- EPS Growth
- DERM N/A
- VTYX N/A
- EPS
- DERM N/A
- VTYX N/A
- Revenue
- DERM $56,134,000.00
- VTYX N/A
- Revenue This Year
- DERM $29.83
- VTYX N/A
- Revenue Next Year
- DERM $54.88
- VTYX N/A
- P/E Ratio
- DERM N/A
- VTYX N/A
- Revenue Growth
- DERM N/A
- VTYX N/A
- 52 Week Low
- DERM $3.20
- VTYX $0.78
- 52 Week High
- DERM $7.29
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- DERM 53.65
- VTYX 42.90
- Support Level
- DERM $5.98
- VTYX $1.02
- Resistance Level
- DERM $6.40
- VTYX $1.18
- Average True Range (ATR)
- DERM 0.62
- VTYX 0.11
- MACD
- DERM -0.06
- VTYX 0.03
- Stochastic Oscillator
- DERM 36.97
- VTYX 65.98
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.